Universal Health Services Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Universal Health Services Inc (UHS). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Acute Care Hospital Services | $2.36B 57.5% | $2.40B 56.1% | $2.61B 58.1% | $2.61B 56.3% |
| Behavioral Health Services | $1.74B 42.4% | $1.88B 43.8% | $1.88B 41.9% | $2.03B 43.7% |
| Other | $2.8M 0.1% | $2.7M 0.1% | $2.9M 0.1% | $2.9M 0.1% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| Managed Care (HMO and PPOs) | $1.18B 28.9% | $1.23B 28.7% | $1.20B 26.7% | $1.20B 25.9% |
| Medicaid | $526.9M 12.9% | $644.1M 15.0% | $709.9M 15.8% | $820.2M 17.7% |
| Managed Medicaid | $602.8M 14.7% | $619.6M 14.5% | $646.6M 14.4% | $653.7M 14.1% |
| Managed Medicare | $520.3M 12.7% | $519.2M 12.1% | $550.1M 12.2% | $548.7M 11.8% |
| Medicare | $468.0M 11.4% | $449.2M 10.5% | $481.7M 10.7% | $478.7M 10.3% |
| Other Non-patient Revenue | $259.7M 6.3% | $266.8M 6.2% | $315.8M 7.0% | $354.6M 7.6% |
| Other Patient Revenue and Adjustments, Net | $310.1M 7.6% | $310.1M 7.2% | $329.3M 7.3% | $310.7M 6.7% |
| UK Revenue | $227.1M 5.5% | $246.9M 5.8% | $261.2M 5.8% | $269.2M 5.8% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.